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http://www.biomedcentral.com/1471-2164/13/710RESEARCH ARTICLE Open AccessThe arthritis severity locus Cia5a regulates the
expression of inflammatory mediators including
Syk pathway genes and proteases in
pristane-induced arthritis
Max Brenner1 and Pércio S Gulko1,2*Abstract
Background: Cia5a is a locus on rat chromosome 10 that regulates disease severity and joint damage in two
models of rheumatoid arthritis, collagen- and pristane-induced arthritis (PIA). In this study, we aimed to identify
cellular and molecular processes regulated by Cia5a using microarray-based gene expression analysis of
synovial tissues from MHC identical DA (severe erosive disease) and DA.F344(Cia5a) congenics (mild non-erosive
disease) rats.
Results: Synovial tissues from six DA and eight DA.F344(Cia5a) rats were analyzed 21 days after the induction of PIA
using the Illumina RatRef-12 BeadChip (21,922 genes) and selected data confirmed with qPCR. There was a
significantly increased expression of pro-inflammatory mediators such as Il1b (5-fold), Il18 (3.9-fold), Cxcl1 (10-fold),
Cxcl13 (7.5-fold) and Ccl7 (7.9-fold), and proteases like Mmp3 (23-fold), Mmp9 (32-fold), Mmp14 (4.4-fold) and
cathepsins in synovial tissues from DA, with reciprocally reduced levels in congenics. mRNA levels of 47 members
of the Spleen Tyrosine Kinase (Syk) pathway were significantly increased in DA synovial tissues compared with
DA.F344(Cia5a), and included Syk (5.4-fold), Syk-activating receptors and interacting proteins, and genes regulated
by Syk such as NFkB, and NAPDH oxidase complex genes. Nuclear receptors (NR) such as Rxrg, Pparg and Rev-erba
were increased in the protected congenics, and so was the anti-inflammatory NR-target gene Scd1 (54-fold
increase). Tnn (72-fold decrease) was the gene most significantly increased in DA.
Conclusions: Analyses of gene expression in synovial tissues revealed that the arthritis severity locus Cia5a
regulates the expression of key mediators of inflammation and joint damage, as well as the expression of members
of the Syk pathway. This expression pattern correlates with disease severity and joint damage and along with the
gene accounting for Cia5a could become a useful biomarker to identify patients at increased risk for severe and
erosive disease. The identification of the gene accounting for Cia5a has the potential to generate a new and
important target for therapy and prognosis.
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Rheumatoid arthritis (RA) is a common, chronic and po-
tentially debilitating form of autoimmune erosive arth-
ritis. Advances in the understanding of RA pathogenesis
have led to the development of new and better treat-
ments [1-3]. Yet, sustained remission is still rarely
achieved [4], and more effective therapies are needed.
The identification of genes implicated in the regulation
of arthritis severity and articular damage has the poten-
tial to generate new and potentially better targets for
therapies aimed at preserving joint architecture and
function, and reducing the risk of developing joint de-
formities. Yet, little is known about those genes [5], and
the large cohorts of RA patients used in genome-wide
association studies for susceptibility were not designed
to address disease severity and articular damage.
We have previously identified several disease severity
and articular damage quantitative trait loci (QTL) in rat
models of RA [6-10]. Using a combination of positional
cloning and functional studies that include transcriptome
analyses of synovial cells and synovial tissues we are be-
ginning to understand the molecular processes regulating
arthritis severity and joint damage in pristane- and
collagen-induced arthritis (PIA and CIA) [10-14]. Similar
strategies have been successfully used to identify other
autoimmunity genes in rodent models [15,16].
Cia5a is a 20.6Mb QTL on rat chromosome 10 that
regulates arthritis severity, cartilage and bone damage,
synovial hyperplasia and inflammation in both PIA and
CIA [9,10]. In the present study we used synovial tissues
from arthritis-protected DA.F344(Cia5a) congenics and
from arthritis-susceptible and MHC-identical DA rats in
a microarray analysis of gene expression. We determined
that the Cia5a locus regulates the expression of several
genes central to RA pathogenesis and joint damage, such
as cytokines Il1b and Il18, chemokines, proteases, med-
iators of the synthesis of reactive oxygen species and
prostaglandins, and genes involved in Toll-like receptor
signaling. Additionally, the expression of 47 members of
the Syk kinase pathway genes, including NFκB genes
were significantly regulated by the Cia5a locus. Further-
more, the presence of F344 alleles at the Cia5a interval
was associated with increased expression of anti-
inflammatory genes, including nuclear receptors and
Timp3, suggesting that the Cia5a locus contains a gene
involved in maintaining an inflammation-free synovial
tissue.
Results
DA.F344(Cia5a) congenics develop a mild form of PIA
with a distinct pattern of gene expression compared
with DA rats
DA.F344(Cia5a) rats developed a significantly milder
form of PIA compared with DA rats [median arthritisseverity score (25–75 percentiles), DA=26.5 (17–36.9),
DA.F344(Cia5a)=5.5 (3.6-7.2); p=0.002, Mann–Whitney
test; Figure 1A and B].
36% (7,925) of the genes in the RatRef-12 BeadChip
were consistently expressed in synovial tissues. Nearly
one-third of these genes (2,648) met the filtering criteria
for differential expression (fold-difference ≥1.5 and
p≤0.01). The presence of F344 alleles at the Cia5a inter-
val, as in DA.F344(Cia5a) congenic rats, was associated
with increased expression of 1,241 genes and reduced
expression of 1,407 genes compared with DA. 134 genes
had a ≥5-fold difference between strains (Figure 1C). 46
genes had a ≥10-fold difference in expression, of which
19 were increased and 27 decreased in congenics, com-
pared with DA (Tables 1 and 2).
Expression of pro-inflammatory genes, proteases
(including matrix metalloproteases, MMPs) and adhesion
molecules was significantly increased in DA and
decreased in DA.F344(Cia5a)
The 1,407 genes with increased expression in DA and
reciprocally decreased expression in DA.F344(Cia5a)
congenics included pro-inflammatory cytokines and che-
mokines implicated in arthritis pathogenesis such as Il1b
(5.17-fold on microarray, and 2.46-fold on qPCR), Il18,
Mif, Ccl2, Ccl7 and Cxcl13 (Table 3 and Additional file
1: Table S3 and Additional file 2: Table S4). Genes with
significantly decreased expression in congenics also
included those implicated in the development of cartil-
age and bone erosions such as MMPs (Mmp3 [24-fold],
Mmp9 and Mmp14), and other proteases (cathepsins D,
E, K and S) (Table 3 and Figure 2). Interestingly, Syk (see
below) has been shown to regulate the expression of dif-
ferentially expressed MMPs such as Mmp3 [17] and
Mmp9 [18], further suggesting a potential central role
for Syk in arthritis and a Syk-regulatory effect of Cia5a.
Components of the extracellular matrix (ECM; Cthrc1,
Col12a1, Emilin1) also had reduced expression in con-
genics, and together with the levels of proteases sug-
gested that there was reduced matrix turnover and
reduced degradation, compared with arthritic DA rats
(Table 3).
Adhesion molecules required for leukocyte migration
into the synovium were increased in DA synovial tissues
and decreased in DA.F344(Cia5a), including integrins
Itga5, Itgam, Itgb2, Itgb7, and Cd44 (Table 3). Cadherin-
11 (Cdh11), a FLS-specific gene required for cell-cell
interactions and implicated in FLS invasion and synovial
hyperplasia was also decreased in DA.F344(Cia5a) con-
genics, consistent with the non-hyperplastic synovial tis-
sue previously described in this strain, as opposed to the
highly hyperplastic synovial tissue seen in DA [10].
The gene with the most significantly increased expres-
sion in DA versus DA.F344(Cia5a) was Tnn (Tenascin
Figure 1 DA and DA.F344(Cia5a) rats differ in arthritis severity and have different synovial gene expression profiles. (A) Map of the
Cia5a locus on rat chromosome 10, and the congenic interval boundaries (black=homozygous for F344 alleles; white=homozygous for DA alleles;
grey=recombination interval). (B) DA rats had severe disease at 21 days post-induction of PIA; DA.F344(Cia5a) congenics were protected and
developed a significantly milder form of arthritis (p=0.002, Mann–Whitney test; boxes show the median and 25%-75% percentiles). (C) 7,925
genes were expressed in all synovial tissues. 2,648 (33.4%) met the 1.5-fold difference and p-value of ≤0.01 (t-test) for significant difference.
134 genes differed by ≥5-fold and less <10-fold, and 46 genes differed by ≥10-fold (inset).
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osteogenesis and angiogenesis but not in arthritis or
inflammation.
These results demonstrate that DA rats with PIA have
increased synovial expression of many genes implicatedTable 1 Genes with ≥10-fold reduction in expression in DA.F3
Symbol Name
Tnn Tenascin N
Mmp9 Matrix metallopeptidase 9
Cdc2 Cell division cycle 2, G1 to S and G2 to M
Mmp3 Matrix metallopeptidase 3
Ccnb2 Cyclin B2
Cthrc1 Collagen triple helix repeat containing 1
Col12a1 Collagen, type XII, alpha 1
Slpi Secretory leukocyte peptidase inhibitor
Spc24 SPC24, NDC80 kinetochore complex component, homol
Emilin1 Elastin microfibril interfacer 1
Prc1 Protein regulator of cytokinesis 1
Emb Embigin
Nuf2 NUF2, NDC80 kinetochore complex component, homolo
Lbp Lipopolysaccharide binding protein
Cks2 CDC28 protein kinase regulatory subunit 2
Wisp1 WNT1 inducible signaling pathway protein 1
Cxcl1 Chemokine (C-x-C motif) ligand 1
Steap1 Six transmembrane epithelial antigen of the prostate 1
LOC687334 Similar to cytoskeleton associated protein 2in RA pathogenesis, further validating the molecular
similarities between PIA and RA, and underscoring the
potential relevance of both Cia5a in arthritis pathogen-
esis and the present study in discovering new key genes
and pathways regulating arthritis.44(Cia5a) compared with DA




















Table 2 Genes with ≥10-fold increased expression in DA.F344(Cia5a) compared with DA *
Symbol Name Entrez Gene ID Fold increase p-value
Scd1 Stearoyl-Coenzyme A desaturase 1 246074 54.62 8.8x10-5
Mpz Myelin protein zero 24564 39.80 7.7x10-5
Akr1c19 Aldo-keto reductase family 1, member C19 307096 26.45 3.0x10-6
Nnat Neuronatin 94270 22.08 5.2x10-7
Ces3 Carboxylesterase 3 113902 21.06 5.4x10-6
Mup5 Major urinary protein 5 298107 18.41 9.5x10-5
LOC688457 Similar to Major urinary protein precursor (MUP) 688457 17.42 1.7x10-4
Abcd2 ATP-binding cassette, sub-family D (ALD), member 2 84356 16.95 4.2x10-6
S100b S100 calcium binding protein B 25742 16.81 8.9x10-8
Tshr Thyroid stimulating hormone receptor 25360 16.61 1.8x10-7
LOC689147 Hypothetical protein LOC689147 689147 15.84 7.9x10-6
Thrsp Thyroid hormone responsive 25357 15.76 1.2x10-5
LOC259244 Alpha-2u globulin PGCL3 259244 15.74 1.8x10-4
Mup4 Major urinary protein 4 362527 15.38 9.9x10-5
Omd Osteomodulin 83717 13.82 5.8x10-6
Plekhb1 Pleckstrin homology domain containing, family B (evectins) member 1 64471 13.26 2.9x10-5
Ankrd5 Ankyrin repeat domain 5 296184 13.14 4.3x10-5
Cidea Cell death-inducing DNA fragmentation factor,a subunit-like effector A 291541 12.91 2.4x10-6
Atp1a2 ATPase, Na+/K+ transporting, alpha 2 polypeptide 24212 12.62 6.9x10-5
Pck1 Phosphoenolpyruvate carboxykinase 1 (soluble) 362282 11.95 2.4x10-5
Mrap Melanocortin 2 receptor accessory protein 288271 11.80 1.8x10-7
Timp3 TIMP metallopeptidase inhibitor 3 25358 11.48 2.9x10-9
MGC72973 Beta-glo 361619 11.38 1.4x10-6
Plp1 Proteolipid protein 1 24943 11.33 1.3x10-5
Plin Perilipin 25629 10.99 9.1x10-7
Adipoq Adiponectin, C1Q and collagen domain containing 246253 10.96 3.3x10-6
Pcbd1 Pterin-4 a-carbinolamine dehydratase/dimerizationcofactor of hepatocyte nuclear factor 1 a 29700 10.74 5.8x10-8
* Bold= nuclear receptor-inducible gene.
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tyrosine kinase) pathway in DA synovial tissues, and
reciprocally decreased expression in DA.F344(Cia5a)
47 members of the Syk pathway were expressed in sig-
nificantly increased levels in DA, and in reduced levels
in congenics (Table 4, and Figures 2 and 3). These
included: a) Syk-activating receptors such as Fcgr2a,
Fcer1g, integrins (Itga5, Itgb2, Itgam), c-lectin receptors
(Clec4a3, Clec7a [Dectin 1], Clec11a), Trem2 and Dap12
(Tyrobp), b) Syk (5.4-fold) itself, c) Syk-interacting and
downstream signaling genes including Vav1, Lcp2
(Slp76), Ptk2b (Pyk2), Lat, Rac2, and Ezr (Vil2), and d)
genes belonging to pathways activated by Syk and impli-
cated in arthritis pathogenesis and synovial hyperplasia
and pannus formation such as NFκB pathway genes
(Fadd, Ikbkb, Nfkb1, Nfkb2), cytokines (Il1b, Ltb, Mif ),
genes implicated in cell proliferation (Ccnb2, Cdc2,Cks2, Nuf2), cytoskeleton regulation (Actr3, Arpc4,
Coro1b, Ezr/Vil2, Myo9b, Parva, Tubb5), and NAPDH
oxidase complex genes implicated in the production
of reactive oxygen species (ROS) (Ncf1, Ncf2, Ncf4,
Cyba) (Table 4).
Interestingly, genes that neutralize ROS (Cat, Sod1,
Gss) went on the opposite direction with increased ex-
pression in congenics (Table 5).
Additionally, Syk and Vav1 expression levels corre-
lated with the cumulative arthritis severity score
(Pearson’s correlation coefficient of 0.8 and p=0.0006
for both genes). Taken together, these observations sug-
gest that the Cia5a QTL contains an arthritis gene that
directly or indirectly regulates the expression of Syk
pathway genes, providing a possible mechanistic ex-
planation for this locus’ effect on the regulation of
disease severity.
Table 3 Mediators of inflammation and articular damage up-regulated in DA synovium and down-regulation in
DA.F344(Cia5a)
Gene Symbol Gene Name Entrez Gene ID Fold DA/Cia5a p-value*
Cytokines and chemokines
Il1b interleukin 1 beta 24494 5.17 0.002
Il18 interleukin 18 29197 3.91 0.0002
Ltb lymphotoxin beta 361795 3.77 0.0002
Mif macrophage migration inhibitory factor 81683 2.37 0.0002
Aif1 allograft inflammatory factor 1 29427 2.48 0.0001
Ccl2 chemokine (C-C motif) ligand 2 24770 3.95 0.01
Ccl7 chemokine (C-C motif) ligand 7 287561 7.90 0.002
Cxcl1 chemokine (C-X-C motif) ligand 1 81503 10.88 0.0004
Cxcl13 chemokine (C-X-C motif) ligand 13 498335 7.53 0.000004
Proteases
Mmp3 matrix metallopeptidase 3 171045 23.94 0.0001
Mmp9 matrix metallopeptidase 9 81687 32.79 0.000000001
Mmp14 matrix metallopeptidase 14 81707 4.46 0.000000004
Mmp19 matrix metallopeptidase 19 304608 5.63 0.0000003
Ctsc cathepsin C 25423 2.64 0.00007
Ctsd cathepsin D 171293 1.90 0.000002
Ctse cathepsin E 25424 2.03 0.0002
Ctsk cathepsin K 29175 3.20 0.0000003
Ctss cathepsin S 50654 1.68 0.002
Extra-cellular matix
Cthrc1 collagen triple helix repeat containing 1 282836 17.93 0.000000003
Col12a1 collagen, type XII, alpha 1 25683 16.25 0.00000008
Emilin1 elastin microfibril interfacer 1 298845 13.55 0.000002
Adhesion molecules
Itga5 integrin alpha 5 (fibronectin receptor alpha) 315346 3.47 0.00000001
Itgam integrin alpha M 25021 3.58 0.0001
Itgav integrin alpha V 296456 1.61 0.0004
Itgb2 integrin beta 2 309684 3.44 0.0001
Itgb7 integrin, beta 7 25713 3.86 0.002
Cd44 Cd44 molecule 25406 1.83 0.005
Cdh11 cadherin 11 84407 1.87 0.003
Toll-like receptors and regulators of their activity
Cd14 CD14 60350 2.13 0.001
Irak4 interleukin-1 receptor-associated kinase 4 300177 1.65 0.0004
Lpb lipopolysaccharide binding protein 29469 4.36 0.0003
Myd88 myeloid differentiation primary response gene 88 301059 1.59 0.002
Pycard PYD and CARD domain containing 282817 1.95 0.0004
Tlr2 toll-like receptor 2 310553 4.36 0.000
Tlr6 toll-like receptor 6 305353 1.76 0.001
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Table 3 Mediators of inflammation and articular damage up-regulated in DA synovium and down-regulation in
DA.F344(Cia5a) (Continued)
Prostaglandin and leukotriene synthesis
Ptgs2 prostaglandin-endoperoxide synthase 2 29527 9.73 0.0006
Pla2g4a phospholipase A2, group IVA (cytosolic, calcium-dependent) 24653 2.04 0.0004
*t-test.
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expression of innate immune response-activating genes,
including members of the inflammasome
Expression levels of genes implicated in innate immune
responses were significantly increased in DA, and decreased
in DA.F344(Cia5a). In addition to the Syk pathway, and
mediators of ROS synthesis, and regulators of cytokine
transcription such as members of the NFκB pathways dis-
cussed above, DA.F344(Cia5a) congenics also had reduced
expression of AP-1 genes (Fos and JunB), Il1b and other
members of the inflammasome (Card11, Nalp3 [both
detected only in DA], and Pycard). Pattern recognition
receptors such as Zbp1 and Lgp2 (both detected only in
DA), and components of the toll-like receptor (TLR) path-
way (Cd14, Ikbke, Irak4, Lbp, MyD88, Tlr2, Tlr6, Ticam1;
Table 3) were expressed in increased levels in DA and
decreased in congenics. Interestingly, and in line with
these observations, the expression levels of negativeFigure 2 qPCR validation of the microarray results. Genes expressed in
increased levels in DA.F344(Cia5a) congenics (three genes, grey bars) were
The same RNAs used in the microarray experiments were used for qPCR. Δregulators of TLR signaling such as Ptpn11 and Pparg was
conversely increased in congenics, suggesting that the
arthritis gene located within the Cia5a QTL might medi-
ate the balance between activating and inhibitory signals
implicated in TLR signaling.
Genes implicated in the synthesis of prostaglandins
and leukotrienes (Pla2g4a, Ptgs2/Cox2, Ptges) were also
increased in DA (Table 3), while genes that counteract
eicosanoid-mediated inflammation (Ptgis, Cyp2j3) were
increased in congenics (Table 5).
Increased expression of anti-inflammatory genes,
including nuclear receptors (NRs), in synovial tissues from
DA.F344(Cia5a) Congenics
Several genes with known anti-inflammatory and cytokine-
suppressing properties were expressed in increased levels in
DA.F344(Cia5a) synovial tissues, and reduced in DA. Theseincreased levels in DA (six genes, black bars) and genes expressed in
selected for qPCR confirmation. Fold-differences were log-transformed.
Ct was used for statistical analyses; all genes had p≤0.04, t-test..
Table 4 Members of the Syk kinase pathway up-regulated in DA synovium compared with down-regulation in
DA.F344(Cia5a)






Fcer1g Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide 25441 2.50 0.0004
Fcgr2a Fc fragment of IgG, low affinity IIa, receptor (CD32) 116591 3.08 0.005
Tcrg T cell receptor gamma locus 24821 3.32 0.0001
Trem2 triggering receptor expressed on myeloid cells 2 301227 2.69 0.0006
Tyrobp Tyro protein tyrosine kinase binding protein 361537 4.80 0.0001
Integrins
Itgam integrin alpha M 25021 3.58 0.0001
Itgav integrin alpha V 296456 1.61 0.0004
Itga5 integrin alpha 5 (fibronectin receptor alpha) 315346 3.47 0.00000001
Itgb2 integrin beta 2 309684 3.44 0.0001
Itgb7 integrin, beta 7 25713 3.86 0.002
c-type lectin receptors
Clec4a1 C-type lectin domain family 4, member a1, Dcir4 362430 2.38 0.001
Clec4a3 C-type lectin domain family 4, member a3, Dcir3 362431 3.00 0.0004
Clec7a C-type lectin domain family 7, member a, Dectin 1 502902 8.48 0.001
Clec11a C-type lectin domain family 11, member a, Scgf 29313 4.24 0.00000008
Syk and Syk-binding and intermediate partners
Ezr** ezrin 54319 2.42 0.0001
Lat linker for activation of T cells 81511 3.83 0.000001
Lcp2 lymphocyte cytosolic protein 2 155918 2.02 0.007
Ptk2b PTK2B protein tyrosine kinase 2 beta 50646 2.54 0.0000002
RhoG ras homolog gene family, member G (rho G) 308875 1.54 0.0008
RhoH ras homolog gene family, member H 305341 2.25 0.001
Syk spleen tyrosine kinase 25155 5.43 0.00004
Vav1 vav 1 guanine nucleotide exchange factor 25156 4.60 0.0001
NFκB genes and
pathway
Ikbkb inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta 84351 1.60 0.0006
Ikbke inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase
epsilon
363984 1.64 0.0001
Nfkb1 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 81736 1.88 0.002
Nfkb2 nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, p49/
p100
309452 1.98 0.00003
Cytokine and chemokine transcription§
Ccl2 chemokine (C-C motif) ligand 2 24770 3.95 0.01
Ccl7 chemokine (C-C motif) ligand 7 287561 7.90 0.002
Il1b interleukin 1 beta 24494 5.17 0.002
Ltb lymphotoxin beta (TNF superfamily, member 3) 361795 3.77 0.0002
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Table 4 Members of the Syk kinase pathway up-regulated in DA synovium compared with down-regulation in
DA.F344(Cia5a) (Continued)
Cell Proliferation
Cdc2 cell division cycle 2, G1 to S and G2 to M 54237 24.16 0.00002
Ccnb2 cyclin B2 363088 22.95 0.000005
Cks2 CDC28 protein kinase regulatory subunit 2 498709 11.62 0.000006
Prc1 protein regulator of cytokinesis 1 308761 13.08 0.00002
Spc24 SPC24, NDC80 kinetochore complex component, homolog (S. cerevisiae) 363028 14.72 0.000002
Cytoskeletal changes
Actr3 ARP3 actin-related protein 3 homolog (yeast) 81732 1.88 0.0001
Arpc4 actin related protein 2/3 complex, subunit 4 297518 1.61 0.00005
Capzb capping protein (actin filament) muscle Z-line, beta 298584 1.64 0.0003
Coro1b coronin, actin-binding protein, 1B 29474 1.68 0.0001
Myo9b myosin IXb 25486 1.93 0.00003
Tiam2 T-cell lymphoma invasion and metastasis 2 308142 2.61 0.00003
Parva parvin, alpha 57341 2.19 0.00005
Reactive oxygen species production
Cyba cytochrome b-245, alpha polypeptide 79129 2.72 0.00001
Ncf1 neutrophil cytosolic factor 1 114553 6.00 0.0001
Ncf2 neutrophil cytosolic factor 2 364018 4.75 0.0003
Ncf4 neutrophil cytosolic factor 4 500904 2.46 0.004
Rac2¶ ras-related C3 botulinum toxin substrate 2 (small GTP binding protein
Rac2)
366957 2.32 0.0007
Syk gene is underlined. * t-test;
§=All four chemokine and cytokine listed genes are NFkB-inducible targets.
** Ezrin is also involved in cytoskeleton regulation.
¶ Rac also regulates NFkB activity, cytoskeleton and cell proliferation.
Figure 3 Syk pathway genes and Syk-regulated cellular processes. Genes, gene families and cellular processes with members expressed in
increased levels in DA synovial tissues, and significantly reduced levels in DA.F344(Cia5a) congenics.
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Table 5 Anti-inflammatory genes and nuclear receptors up-regulated in DA.F344(Cia5a) congenics
Gene Symbol Gene Name Entrez Gene ID Fold difference DA/Cia5a p-value*
Anti-inflammatory and regulators of immune responses
Scd1 stearoyl-Coenzyme A desaturase 1 246074 54.62 0.0001
Timp3 TIMP metallopeptidase inhibitor 3 25358 11.48 0.000000003
Adipoq adiponectin, C1Q and collagen domain
containing
246253 10.96 0.000003
Ptpn11 protein tyrosine phosphatase, non-receptor
type 11
25622 4.18 0.00002
Cyp2j3 cytochrome P450, family 2, subfamily j,
polypeptide 3
313375 3.38 0.002
Ptgis prostaglandin I2 (prostacyclin) synthase 25527 2.63 0.0003
Cat catalase 24248 1.91 0.002
Gss glutathione synthetase 25458 1.56 0.001
Sod1 superoxide dismutase 1, soluble 24786 1.53 0.00002
Nuclear receptors and an interacting protein
Rxrg retinoid X receptor gamma, Nr2b3 83574 5.39 0.0001
Pparg peroxisome proliferator-activated receptor
gamma, Nr1c3
25664 5.32 0.00005
Rev-erba Nr1d1 252917 3.41 0.004
Arp1 Nr2f2 113984 2.45 0.0002
Nrip1 nuclear receptor interacting protein 1 304157 2.35 0.00004
Thrb thyroid hormone receptor beta, Nr1a2 24831 2.07 0.002
Thra thyroid hormone receptor alpha, Nr1a1 81812 1.97 0.001
Ncor1 nuclear receptor co-repressor 1 54299 1.89 0.003
Rora RAR-related orphan receptor alpha, Nr1f1 300807 1.88 0.0001
Lxra Liver X receptor alpha, Nr1h3 58852 1.52 0.0006
* t-test.
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Thrb (Table 5).
Scd1 was the gene with the most significantly
increased expression in DA.F344(Cia5a) congenics with
a 55-fold difference compared with DA (Tables 2 and 5).
Scd1 has been shown to reduce cytokine levels and to have
anti-inflammatory activity [19,20]. We have previously
reported that Scd1 is expressed in significantly reduced
levels in synovial tissues from rats with severe arthritis,
and increased in the synovial tissues of yet another
arthritis-protected congenic strain [14].
Adipoq and Timp3, which is an inhibitor of the TNFα
converting enzyme (TACE), were two additional anti-
inflammatory genes expressed in significantly increased
levels (>10-fold) in DA.F344(Cia5a) (Table 5).
Scd1 and some of the other genes up-regulated in DA.
F344(Cia5a) synovial tissues such as Adipoq, Cidea,
Cd36, Fabp4, Gpd1, Lpl, Lpin1, Mgst1, Plin, Pck1, Slc2a4
and Srebf1, are known to be inducible by NRs (Table 2
and Table 5). These observations suggest that NRs were
not only expressed in increased levels but also hadincreased activity in synovial tissues from DA.F344
(Cia5a) compared with DA.
Genes located within the Cia5a interval have significantly
different expression levels
75 of the 7,925 genes expressed by all samples were
located within the Cia5a interval. 21 of these 75 had
increased expression in DA synovial tissues, and 11 were
increased in the congenics. 14 of these 32 differentially
expressed genes had ≥2-fold-difference. Sphk1 and
Sectm1b were the genes contained within the Cia5a
interval with the most significantly increased expression
in DA (7.58 and 7.61-fold, respectively), while Itgb4 and
DIgr1 and were those with the most significantly
increased expression in DA.F344(Cia5a) congenics (2.77
and 2.85-fold, respectively) (Table 6). Additionally, four
genes located within the Cia5a interval were expressed
only or predominantly in DA synovium, while two other
genes were expressed predominantly in DA.F344(Cia5a)
(Table 6). It is conceivable that these differences in ex-
pression levels of genes located within the Cia5a interval
Table 6 Differentially expressed candidate genes located within the Cia5a interval on rat chromosome 10*
Gene Symbol Gene name Entrez Gene
ID
Difference p-value§
Increased in DA Fold DA/Cia5a
Igsf7 immunoglobulin superfamily, member 7 287813 4.42 0.00008
Lgals3bp lectin, galactoside-binding, soluble, 3 binding protein 245955 3.85 0.000001
RGD1309310 similar to mKIAA0195 protein 303677 3.89 0.00001
Sectm1b secreted and transmembrane 1B 287884 7.61 0.00001
Slc16a3 solute carrier family 16, member 3 80878 5.36 0.000005
Sphk1 sphingosine kinase 1 170897 7.58 0.0000003
Increased in DA.F344(Cia5a) Fold Cia5a/DA
Itgb4 integrin beta 4 25724 2.85 0.0004
RGD1311422 similar to CG8841-PA 287822 2.57 0.002
RGD1561778 similar to dendritic cell-derived immunoglobulin(Ig)-like
receptor 1, DIgR1
303666 2.77 0.002
Slc25a10 solute carrier family 25, member 10 170943 2.15 0.004
Expressed only or predominantly in DA Frequency DA:Cia5a
Cd300lf CD300 molecule-like family, member f 287818 6:0 0.0003
Fdxr ferredoxin reductase 79122 6:1 0.0047
Cd7 CD7 molecule 303747 6:0 0.0003
Sectm1a secreted and transmembrane 1A 287885 6:1 0.0047
Expressed only or predominantly in DA.F344(Cia5a)
Aanat arylalkylamine N-acetyltransferase 25120 0:7 0.0047
Hrnbp3 hexaribonucleotide binding protein 3 287847 1:6 0.1♯
*List contains the most signficantly differentially expressed genes; § t-test was used to compare means for fold-difference calculations and Fisher's Exact test to
compare frequencies. #not statistically significant.
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the 5’ untranslated region (UTR) that affects a transcrip-
tion factor binding site in cis, thus affecting transcription
efficiency, or a 3’ UTR polymorphism affecting mRNA
stability.
Gene targets of microRNAs (miRNA) contained within the
Cia5a interval were not differentially expressed
The Cia5a interval contains six predicted miRNAs. We
considered the possibility that polymorphisms in one of
those six miRNAs could account for the Cia5a effect on
gene expression and arthritis severity. In that case, such
polymorphism would affect the miRNA activity on the
transcription of its target genes. Therefore, we look for
the differential expression of targets of all six predicted
miRNAs located within the Cia5a interval. A list of tar-
get and non-target genes was generated for each of the
six miRNAs, but no significant over-representation of
targets was detected (Figure 4), suggesting that poly-
morphisms affecting the expression or function of the
miRNAs contained within the Cia5a interval are less
likely to explain the differences in gene expression iden-
tified in this study.Analyses of cell type specific genes suggests synovial
tissue cellularity differences between DA and
DA.F344(Cia5a) Congenics
13 genes known to be specifically expressed by the cell
types of interest to this study were used to compare DA
and DA.F344(Cia5a) synovial tissues (Additional file 3:
Table S2). The expression levels of those genes suggested
increased numbers of FLS (consistent with synovial
hyperplasia), macrophages, dendritic cells (DC), neutro-
phils and T cells in the synovial tissues of DA, compared
with congenics (Additional file 3: Table S2). No gene
specific for B cells, NK cells or Tregs were among those
differentially expressed between the two strains, suggest-
ing that the number of these cells in the synovial tissues
of these two strains was not significantly different.
Discussion
Disease severity and articular damage are associated with
increased risk for disability, joint deformities and
reduced life expectancy in patients with RA [21-23]. Yet,
little is known about the genes implicated in the regula-
tion of disease severity and articular damage genes in
RA, and these genes could be the most relevant targets
Figure 4 Differentially expressed predicted targets of the miRNAs located within the Cia5a interval. Six miRNAs map to the Cia5a interval.
The number of predicted target genes of each miRNA that were up-regulated and down-regulated in DA and DA.F344(Cia5a) congenics was not
statistically significant (Chi-square test with the Yates correction). Numbers (percentages intra-parenthesis) of genes expressed in increased levels
(dark grey), reduced levels (light grey) or unchanged (white) in DA compared with DA.F344(Cia5a) are shown.
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ture and function.
We have previously identified Cia5a, a 20.6 Mb arth-
ritis severity and joint damage regulatory locus, on rat
chromosome 10 [10]. Cia5a co-localizes with other arth-
ritis severity loci identified in other rodent models of
arthritis such as oil-induced arthritis (Oia3) [24], and
CIA in a DAxACI intercross (Cia27) [25]. There have
been no genome-wide association or linkage studies of
disease severity and joint damage in RA, and therefore,
it is unknown whether the Cia5a syntenic region on
human chromosome 17q22-q25 harbors a severity or
joint damage arthritis regulatory gene. However, the
human 17q22-q25 region contains a locus previously
linked with RA susceptibility [26]. In the present study
we analyzed synovial tissues from DA rats, which de-
velop severe arthritis (PIA) with pronounced synovial
hyperplasia and cartilage and bone destruction, and syn-
ovial tissues from the DA.F344(Cia5a) congenics, which
develop mild and non-erosive disease. These two strains
share the same MHC and are genetically identical except
for the presence of F344 alleles at the Cia5a interval,
underscoring the magnitude of the effect of this single
locus on clinical disease, on histologic joint damage [10]
and on gene expression (present study). DA.F344(Cia5a)
congenics had significantly reduced expression of genes
previously implicated in RA pathogenesis, RA severity
and articular damage, including Il1b, Il18, Mif, Mmp3
and Mmp14. These and other similarities between DA
rats and RA synovial tissues’ gene expression, such as
increased expression of chemokines, matrix proteins, ad-
hesion molecules, mediators of innate immune
responses, and others, underscore and further validate
the potential clinical relevance of our model and discov-
ery strategy.We identified a new role for Cia5a on the regulation
of the expression of members of the Syk pathway, where
forty-seven genes directly or indirectly related to Syk ac-
tivation were expressed in increased levels in DA, and
significantly reduced levels in DA.F344(Cia5a) congenics.
Syk is a tyrosine kinase that phosphorylates ITAM motifs
in trans-membrane receptors or adaptors, and interacts
with partners like Vav, PI3K and Slp76 [27]. Syk activa-
tion mediates signaling through several cell surface
receptors, including those with significantly different
levels in this study such C-lectin type receptors, Fcer1g,
Fcgr2a, Trem2, Tyrobp, integrins, and the T-cell receptor
(TCR) (Figure 3). Resident and infiltrating inflammatory
cells in the RA synovial pannus, such as mast cells,
macrophages, B and T cells, express these Syk-activating
receptors. These resident cells and infiltrating cells have
been implicated in arthritis pathogenesis and joint dam-
age, raising the possibility that part of their effect may
be mediated by Syk-activating receptors.
Analyses of cell-specific genes suggested reduced num-
bers of macrophages, dendritic cells, neutrophils and T
cells in the synovial tissues of congenics compared with
DA, which is in agreement with our previous histologic
analyses and might explain part, but not all of the differ-
ences in expression of Syk genes. Additionally, DA.F344
(Cia5a) congenics had significantly lower levels of the
FLS-specific gene Cdh11, compatible with the reduced
synovial hyperplasia that we have previously described.
Syk pathway members regulate several cellular processes
implicated in arthritis pathogenesis and articular damage,
ranging from the production of reactive oxygen species,
NFκB activation and the transcription of pro-inflammatory
mediators such as Il1b and Ccl2, to the cell proliferation
required for the development of synovial hyperplasia, and
actin cytoskeleton rearrangements [27]. NFκB activity is
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TLRs and cytokine receptors [28]. The NFκB pathway has
a central role in the production of pro-inflammatory cyto-
kines such as IL-1β, IL-6 and TNFα, in the development
of synovial hyperplasia and in disease severity [29-31].
Actin cytoskeleton rearrangements are also regulated by
the Syk pathway [27], and are required for the migration
of inflammatory cells into the synovial tissue, and for syn-
ovial cells and synovial tissue invasion and destruction of
cartilage [13,32]. Therefore, our observations suggest that
a gene located within the Cia5a interval is a new regulator
of the expression of Syk pathway genes implicated in key
processes in arthritis pathogenesis.
The precise mechanisms whereby Cia5a regulates the
expression of Syk genes remain unclear, and might reflect
differences in tissue cellularity, multiple cell-activating
processes, or a polymorphism in transcription factor
located within the Cia5a interval that affects transcription.
Studies by our group of synovial tissues obtained from
four different congenic strains yielded different results in
gene expression (Brenner et al., manuscript in prepar-
ation) [12,14,33], suggesting that the Syk-regulatory effect
of Cia5a is a specific observation, and not simply related
cellularity differences or inflammation.
Syk has been recently implicated in arthritis pathogen-
esis and joint damage, and Syk-deficient mice are pro-
tected from autoantibody-induced erosive arthritis [34],
and treatment with a SYK inhibitor significantly reduced
disease severity and joint erosions and damage in
collagen-induced arthritis [35]. Both the total and phos-
phorylated forms of SYK are expressed in increased
levels in RA synovial tissues compared with osteoarth-
ritis, and SYK inhibition reduced the expression of IL-6
and MMP-3 [17]. More importantly, the use of a SYK
inhibitor significantly reduced disease activity in patients
with RA [36], with 67%, 43% and 28% of patients achiev-
ing ACR20, ACR50 and ACR70, respectively, in a 3-
month double-blind and placebo-controlled study [37].
Therefore, it is conceivable that the Syk pathway genes
differentially expressed in this study could help identify
patients more likely to benefit from therapy with SYK
inhibitors. Additionally, Syk is critical to TNFα-induced
responses [38], raising the possibility that the Syk path-
way 47-gene signature could be used to predict
increased TNFα activity prior to choosing a biologic
therapeutic agent. Additionally, the increased expression
of Syk pathway genes could identify patients at increased
risk to develop erosive disease and could become a prog-
nostic tool. Lastly, the Cia5a gene itself has the potential
to become a new target for therapies aimed at reducing
articular damage via inhibition of Syk pathway genes, in-
cluding processes downstream from Syk such as NFκB.
While several genes with pro-inflammatory, proteo-
lytic, innate immunity and inflamasome-related activitywere expressed in reduced levels in DA.F344(Cia5a) con-
genics, groups of genes with known anti-inflammatory
properties were expressed in increased levels in con-
genics. These genes included Timp3, Ptpn11, antagonists
of reactive oxygen species (Cat, Gss, Sod1) and nuclear
receptors. Nuclear receptors such as Lxra, Pparg and
Rora have been shown to interfere with NFκB and AP-1
activation [39-41], and to have anti-inflammatory and
arthritis-suppressive properties [42-45]. Rxrg was an-
other nuclear receptor expressed in significantly
increased levels in DA.F344(Cia5a) congenics. While
Rxrg itself has not been studied in the context of arth-
ritis, it dimerizes with Lxra, Pparg, and with Vdr, and is
required for their anti-inflammatory activity. Addition-
ally, several nuclear receptor-inducible genes, including
the inflammation-suppressor Scd1 [20] were expressed
in increased levels in the synovial tissues of the con-
genics. These observations suggest that not only nuclear
receptor levels were increased, but also their activity.
We have recently identified a similar nuclear receptor
expression signature in another arthritis-protective con-
genic strain, DA.ACI(Cia25) [14], suggesting that this ef-
fect is not specific to the Cia5a locus, but more broadly
correlates with preservation of both a normal synovial
environment and articular architecture.
The gene with the most significantly increased expres-
sion in DA compared with congenics was Tnn (Tenascin
N). While little is known about this secreted extra-
cellular matrix glycoprotein, it has been implicated in
cancer-associated angiogenesis [46], and in integrin-
dependent cancer motility [47]. Another member of the
tenascin family, Tenascin C (Tnc), was recently shown to
be an endogenous activator of TLR4, an inducer of IL-6
and TNFα, and was required for joint damage in arth-
ritic mice [48], suggesting that Tnn could have a func-
tion similar to Tnc in arthritis.
Lastly, we considered the possibility that a polymorph-
ism in the 5’ UTR or 3’UTR region of the gene account-
ing for Cia5a could interfere with its transcription and/
or mRNA stability, respectively, leading to increased or
reduced gene-specific mRNA levels. We looked for dif-
ferentially expressed genes and genes preferentially
expressed by only one of the strains and located within
Cia5a as a clue to the above possibility. Thirty-eight
genes met these criteria, and particularly the most sig-
nificant sixteen genes are interesting candidates that will
be studied in detail (Table 6).
Conclusion
In conclusion, in the present study we identified a pattern
of gene expression regulated by Cia5a, which included
several inflammatory mediators and 47 members of the
Syk pathway. Levels of several mediators of arthritis
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were also reduced in DA.F344(Cia5a) congenics, under-
scoring the importance of the gene accounting for this
locus. Increased expression of nuclear receptors correlated
with joint preservation, and a new potential mediator of
inflammation, Tnn, was identified for the first time in syn-
ovial tissues. Our observations suggest that the gene
accounting for Cia5a has the potential to become an im-
portant new target for therapies aimed at preserving joint
architecture free of damage, and reducing inflammation.
Methods
Rats
DA/BklArbNsi (DA) rats were originally purchased from
Bantin & Kingman (Freemont, CA), maintained at the
Arthritis and Rheumatism Branch, National Institute
of Arthritis and Musculoskeletal and Skin Disease, Na-
tional Institutes of Health, and then transferred to the
Feinstein Institute for Medical Research (FIMR; formerly
North Shore-LIJ Research Institute, Nsi). DA.F344
(Cia5a) congenic rats were generated as previously
described [9]. Briefly, a 20.6Mb interval from chromo-
some 10 from the arthritis-resistant F344 strain was
introgressed into arthritis-susceptible DA rats through
genotype-guided breeding (Figure 1A). This strategy
selected for F344 alleles at the Cia5a interval while ex-
cluding donor genome contamination at other loci
known to regulate arthritis [10,49]. Experiments were
done with 8–12 week-old male rats homozygous at the
congenic interval. All experiments were conducted
under an Institutional Animal Care and Use Committee
(IACUC)-approved protocol.
PIA and tissue collection
Male DA (n=6) and DA.F344(Cia5a) (n=8) congenic rats
were anesthetized and injected intradermally with 150 μl
of pristane (MP Bio, Solon, OH) divided into two injec-
tion sites at the base of the tail (day 0) [50]. Arthritis se-
verity was assessed with a previously described 80-point
scoring system [51]. Ankle synovial tissues were col-
lected 21 days post-induction of arthritis.
RNA extraction
Total RNA was extracted from synovial tissues using the
RNeasy Mini Kit (Qiagen, Valencia, CA) according
to the manufacturer's instructions and including a
DNase treatment step. RNA was quantified and assessed
for purity using the NanoDrop spectrophotometer
(Rockland, DE). RNA integrity was verified with the
BioAnalyzer 2100 (Agilent, Palo Alto, CA).
Microarray
All reagents and procedures were previously optimized
for use with the Illumina Whole-Genome Expressionplatform [12]. Briefly, total RNA (200 ng) was amplified
and biotinylated using the TotalPrep labeling kit
(Ambion, Austin, TX). Each individual sample was
hybridized to one individual array in the RatRef-12 Ex-
pression BeadChip (Illumina, San Diego, CA), which
contains 22,522 probes covering 21,922 rat genes
selected primarily from the NCBI RefSeq database (Re-
lease 16). Hybridization was done in Illumina IntelliHyb
chambers, followed by washing and staining with Cy3-
streptavidin. The BeadChip was scanned on a high-
resolution Illumina BeadArray reader using a two-
channel 0.8 μm resolution confocal laser scanner.
cDNA synthesis and quantitative real-time PCR (qPCR)
expression analysis
Differences in the expression of selected genes from the
microarray analyses were validated with qPCR. The
qPCR conditions have been described elsewhere [12].
Briefly, total RNA (200 ng) from each sample was
used for cDNA synthesis using Superscript III (Invitro-
gen). Primers and qPCR probes were designed to tar-
get the same exons as the corresponding Illumina
RatRef-12 Expression BeadChip probes (Additional file
4: Table S1). We used Universal ProbeLibrary (Roche,
Indianapolis, IN) and Taqman (ABI, Applied Biosys-
tems, Foster City, CA) probes labeled with FAM at the
5' end and TAMRA at 3' end. Reactions were prepared
in duplicates with Eurogentec qPCR MasterMix
(San Diego, CA), and run on an ABI Prism 7700 ther-
mocycler using SDS software version 1.9.1 (ABI). Ct
(threshold cycle) values were adjusted for Gapdh in
each sample (ΔCt). Expression levels (ΔCt) were com-
pared using the t-test and a p-value ≤0.01 was consid-
ered significant. Fold-differences were calculated with
the 2-ΔΔCt method [52].
MicroRNAs (miRNA)
We considered the possibility that polymorphisms in a
miRNA located within the Cia5a interval could account
for the Cia5a effect on gene expression and arthritis se-
verity. In that case, such polymorphism would affect the
miRNA activity on the transcription of its target genes.
Therefore, we looked for miRNAs mapping to the Cia5a
interval using the miRBase [53]. Target genes for the
miRNAs contained within the Cia5a interval were pre-
dicted with TargetScan [54]. Enrichment for differentially
expressed predicted targets of miRNAs located within
Cia5a was calculated using the Chi-square test with the
Yates correction.
Cellular subset gene expression signatures
Differences in tissue resident and infiltrating cell popula-
tions can affect the interpretation of gene expression
analyses. We looked for cell-specific genes using the
Brenner and Gulko BMC Genomics 2012, 13:710 Page 14 of 16
http://www.biomedcentral.com/1471-2164/13/710GNF Mouse GeneAtlas V3 (Affymetrix MOE430, GEO
code GSE10246), a database containing gene expression
information for 96 resting and stimulated mouse cell
types and tissues [55,56], as well as the BioGPS website
(www.biogps.org, Scripps Research Institute). The GNF
Mouse GeneAtlas V3 did not include fibroblast-like
synoviocytes (FLS) or regulatory T cells (Tregs). There-
fore, additional non-redundant cell signature genes were
obtained from the literature to represent FLS and Tregs
[57-65]. We generated a list of genes specific for B cells,
T cells, Treg cells, NK cells, FLS, dendritic cells, mast
cells, macrophages and neutrophils. We next looked for
those cell-specific genes within the list of genes differen-
tially expressed between DA and DA.F344(Cia5a) con-
genics, as well as in the list of genes preferentially
expressed, or only expressed in one strain and not in the
other in order to gain insight into differences in cell
populations.
Microarray analysis and statistics
Microarray fluorescence intensities were extracted using
BeadStudio 2.0 (Illumina). Fluorescent intensities were
background-subtracted and then normalized using the
cubic spline algorithm. Normalized data were log2-trans-
formed prior to all analyses. Probes consistently
expressed in all arrays were included in the analyses.
Genes with ≥1.5-fold difference in intensity between DA
and DA.F344(Cia5a) and a t-test p-value ≤ 0.01 were
considered differentially expressed and selected for path-
way detection analyses using IPA 5.5.1 (Ingenuity Sys-
tems, Redwood City, CA), as well as public online
databases (Ensembl, Genecards, Oncomine, BioGPS, Rat
Genome Database) and literature search (Pubmed).
Strain-specific (genes only in one of the strains), or
preferential strain (genes expressed in a higher percent-
age of rats of one strain, and in lower percentage of rats
of the other strain) gene expression was determined with
the Fisher’s exact test.
Enrichment for biological functions and disease
groups was determined with the IPA software and
calculated using the Fisher’s exact test with the
Benjamini-Hochberg correction and a cutoff p-value
of ≤0.05. Enrichment for differentially expressed
genes within specific cell subsets, or genes located
within the Cia5a interval was calculated using the
Fisher’s exact test. Non-normally distributed arthritis
severity scores were compared using the Mann–
Whitney test.
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